All In Biotech

Drug Trial Radar · NCT05901935

DP303c in Patients With HER2-positive Advanced Breast Cancer

A Multicentre, Randomized, Open-label, Controlled Phase Ш Clinical Study to Evaluate the Efficacy and Safety of DP303cversus Trastuzumab Combined With Vinorelbine/Capecitabine in of HER2-positive Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Jul 2023

Primary completion

Jan 2026

Study completion Jul 2028

Sponsor

Sponsor type
Industry
First posted
Jun 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of DP303c in patients with HER2-positive advanced breast cancer.

Conditions

  • HER2-positive Advanced Breast Cancer

Interventions

  • DP303cDrug

    DP303c injection, 3.0 mg/kg, Q3W.

  • TrastuzumabDrug

    IV, 6 mg/kg, D1, Q3W

  • Vinorelbine TartrateDrug

    IV, 25 mg/m\^2,D1、D8,Q3W

  • Capecitabine tabletsDrug

    PO 1000 mg/m\^2, bid, D1-D14, Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) by BIRCTime frame: Up to approximately 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.